Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis

Nature Biotechnology

Volumn 18, Issue 8, 2000, Pages 862-867

  Zhang, H ^a   Cook, J ^a   Nickel, J ^a   Yu, R ^a   Stecker, K ^a   Myers, K ^a   Dean, N M ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

Antisense oligonucleotide; Apoptosis; Fas; Hepatitis

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; FAS ANTIGEN; MESSENGER RNA; OLIGONUCLEOTIDE;

ANIMAL CELL; APOPTOSIS; ARTICLE; AUTOIMMUNE HEPATITIS; CHEMICAL MODIFICATION; CONCENTRATION RESPONSE; HEPATITIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIGENS, CD95; BASE SEQUENCE; DNA PRIMERS; GENE EXPRESSION REGULATION; HEPATITIS, ANIMAL; LIVER; MICE; OLIGONUCLEOTIDES, ANTISENSE; RNA, MESSENGER;

EID: 0033891369     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/78475     Document Type: Article

References (48)

1. The Fas death factor
2. Apoptosis mediated by the Fas system
3. CD95-induced apoptosis in human liver disease
4. Essential roles of the fas ligand in the development of hepatitis
5. Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis
6. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin
7. Evidence for Fas-dependent and Fas-independent mechanisms in the pathogenesis of experimental autoimmune encephalomyelitis
8. CD95 (APO-1/Fas)-mediated apoptosis in colon epithelial cells: A possible role in ulcerative colitis
9. Fas and Fas ligand expression in the salivary glands of patients with primary Sjogren's syndrome
10. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis
11. Fas/Fas ligand-driven T cell apoptosis as a consequence of ineffective thyroid immunoprivilege in Hashimoto's thyroiditis
12. Fas ligand, tumor necrosis facter-a expression, and apoptosis during allograft rejection and tolerance
13. Involvement of the CD95 (APO-1/Fas) receptor and ligand system in Helicobacter pylori-induced gastric epithelial apoptosis
14. Therapeutic effect of an anti-Fas ligand mAb on lethal graft-versus-host disease
15. Pharmacology of antisense oligonucleotide inhibitors of protein expression
16. Basic principles of antisense therapeutics
17. Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides
18. Modification of pre-mRNA splicing by antisense oligonucleotides
19. Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters
20. Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant
21. Antisense oligonucleotides directed against the viral RNA polymerase gene enhance survival of mice infected with influenza A
22. An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice
23. In vivo targeting of inducible NO synthase with oligodeoxynucleotides protects rat kidney against ischemia
24. Oligonucleotide-based inhibition of embryonic gene expression
25. Molecular mechanisms of antisense drugs: RNase H
26. Characterization of a potent and specific class of antisense oligonucleotide inhibitors of human PKC-alpha expression
27. Disparate roles for TNF-α and fas ligand in concanavalin A-induced hepatitis
28. Concanavalin A induces perforin-mediated but not Fas-mediated hepatic injury
29. Lethal effect of the anti-Fas antibody in mice
30. Raised plasma-soluble fas and fas-ligand in alcoholic liver disease
31. Protection of acetaminophen-induced hepatocellular apoptosis and necrosis by cholesteryl hemisuccinate pretreatment
32. Histology of acetaminophen-induced liver changes: Role of interleukin 1 α and tumor necrosis factor α
33. A T cell-dependent experimental liver injury in mice inducible by concanavalin A
34. Fas antigen expression in liver tissues of patients with chronic hepatitis B
35. Fas system and apoptosis in viral hepatitis
36. In situ investigation of Fas/FasL expression in chronic hepatitis B infection and related liver diseases
37. Hepatic Fas antigen expression before and after interferon therapy in patients with chronic hepatitis C
38. Expression of Fas antigen on hepatocytes in viral hepatitis patients
39. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of fas
40. Hepatic failure and liver cell damage in acute Wilson's disease involve CD95 (APO-1/Fas) mediated apoptosis
41. Glandular and extraglandular expression of the Fas-Fas ligand and apoptosis in patients with Sjogren's syndrome
42. CD40 activation induces apoptosis in cultured human hepatocytes via induction of cell surface fas ligand expression and amplifies fas-mediated hepatocyte death during allograft rejection
43. Contribution of Fas ligand to T cell-mediated hepatic injury in mice
44. - mice
45. 2'-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells
46. Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes
47. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression
48. Quantitation of phosphorothioate oligonucleotides in human plasma